H.C. Wainwright Lowers PT on United Therapeutics Corporation (UTHR) to $400 From $425, Keeps a Buy Rating
United Therapeutics Corporation (NASDAQ:UTHR) is one of the top cheap pharmaceutical stocks to buy now. H.C.
United Therapeutics Corp (UTHR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 2,370,000 | $681,019,500 | -12% | 11.93% |
| 2. | Renaissance Technologies Jim Simons | 2,119,092 | $608,921,086 | +1% | 0.81% |
| 3. | AQR Capital Management Cliff Asness | 1,273,161 | $362,876,291 | +41% | 0.3% |
| 4. | Deerfield Management James E. Flynn | 540,626 | $155,348,881 | +97% | 2.82% |
| 5. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 339,092 | $97,438,086 | -15% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.83 | 4 | $331.32 | 1,684 | 2019-06-10 | Filing | |
| $114.06 | 6 | $684.36 | 1,686 | 2018-04-20 | Filing | |
| $126.20 | 5 | $631.00 | 1,685 | 2017-11-20 | Filing | |
| $128.35 | 3 | $385.05 | 1,686 | 2017-07-28 | Filing | |
| $130.24 | 3 | $390.72 | 1,683 | 2017-07-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $310.25 | 2,095 | $649,970.61 | 36,781 | 2025-08-21 | Filing | |
| $309.43 | 4,234 | $1,310,121.96 | 38,876 | 2025-08-21 | Filing | |
| $308.43 | 2,330 | $718,637.47 | 43,110 | 2025-08-21 | Filing | |
| $307.39 | 1,441 | $442,943.08 | 45,440 | 2025-08-21 | Filing | |
| $306.12 | 300 | $91,836.99 | 46,881 | 2025-08-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,333,708 | $1,532,641,018 | 0.03% | |
| 2. | 4,448,848 | $1,278,376,474 | 0.02% | |
| 3. | 2,167,511 | $622,834,286 | 0.02% | |
| 4. | 1,442,936 | $414,627,659 | 0.08% | |
| 5. | 1,200,365 | $344,261,060 | 0.02% |
News See All
11 Cheap Pharmaceutical Stocks to Buy Now
The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the steps they should take to decrease the prices of US prescription drugs to “most...
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript July 30, 2025United Therapeutics Corporation misses on earnings expectations.
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus
Liquidia Corporation (NASDAQ:LQDA) is one of the biotech stocks to buy according to Wall Street analysts.
Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT
United Therapeutics Corporation (NASDAQ:UTHR) is one of the most profitable biotech stocks to invest in now.
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts.
10 Most Profitable Biotech Stocks to Invest in Now
Jared Holz, Mizuho health care equity strategist, appeared on CNBC’s 'Power Lunch' on March 5 to talk about investing in biotech and the oversaturation in the sector.
TD Cowen maintained a Buy rating on United Therapeutics (UTHR), Kept the PT Unchanged
United Therapeutics Corporation (NASDAQ:UTHR) is one of the Best Extremely Profitable Stocks to Buy Right Now. On July 15, Analyst Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics...
12 Best Extremely Profitable Stocks to Buy Right Now
On July 23, Matt Powers, Powers Advisory Group managing partner, joined CNBC for an interview to discuss the latest market trends.
10 Most Undervalued Healthcare Stocks to Buy According to Analysts
The CEO of Pivotal Advisors, Tiffany McGhee, spoke on CNBC on June 27 on what investors should do in light of the current state of the market.
Billionaire Hedge Funds
